-
Product Insights
Juvenile Macular Degeneration (Stargardt Disease) – Drugs In Development, 2023
Global Markets Direct’s, ‘Juvenile Macular Degeneration (Stargardt Disease) - Drugs In Development, 2023’, provides an overview of the Juvenile Macular Degeneration (Stargardt Disease) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Juvenile Macular Degeneration (Stargardt Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...
-
Product Insights
Biliary Tumor – Drugs In Development, 2023
Global Markets Direct’s, ‘Biliary Tumor - Drugs In Development, 2023’, provides an overview of the Biliary Tumor pipeline landscape. The report provides comprehensive information on the therapeutics under development for Biliary Tumor, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Point of Care (POC) Analyzers Pipeline by Development Stages, Segments, Region and Countries, Regulatory Path and Key Companies
Point of Care (POC) Analyzers Pipeline Market Report Overview POC analyzers are small handheld or bench-top analyzers often used in small laboratories and physician labs with less workload and daily sample inflow. They often use disposable test cartridges and can provide faster results. The Point of Care (POC) analyzers pipeline market research report provides a comprehensive understanding of the pipeline products along with their comparative analysis at various stages of development. The report also includes information about the territories wherein...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – (Curcumin + Doxorubicin) in Colorectal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - (Curcumin + Doxorubicin) in Colorectal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. (Curcumin + Doxorubicin) in Colorectal Cancer Drug Details: Imx-110...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Zanidatamab in Adenocarcinoma Of The Gastroesophageal Junction
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Zanidatamab in Adenocarcinoma Of The Gastroesophageal Junction Drug Details: Zanidatamab is under development for the...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – EU-101 in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - EU-101 in Non-Small Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. EU-101 in Non-Small Cell Lung Cancer Drug Details: EU-101 is...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Prp in Gastrointestinal Tract Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Prp in Gastrointestinal Tract Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.PRP in Gastrointestinal Tract Cancer Drug Details:PRP is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Dirloctocogene Samoparvovec in Hemophilia A (Factor VIII Deficiency)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Dirloctocogene Samoparvovec in Hemophilia A (Factor VIII Deficiency) Drug Details:RG-6357 (SPK-8011, SPK-FVIII) is under development for...
-
Company Profile
Spark Therapeutics Inc – Company Profile
Spark Therapeutics Inc (Spark), a subsidiary of F. Hoffmann-La Roche Ltd, is a clinical-stage gene therapy company. It provides gene therapies for inherited retinal diseases (IRDs), hemophilia and pompe disease. The company’s gene therapy vectors used in its programs are engineered using adeno-associated virus. Spark’s SPK-RPE65 is intended to cure rare blinding conditions caused by mutations in the RPE65 gene. The company provides various services such as discovery research, manufacturing, product development and regulatory advancement and U.S. commercialization. It collaborates...
Add to Basket -
Product Insights
Huntington Disease Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Huntington's disease (HD) is an inherited disease that causes certain nerve cells in the brain to waste away. This is a familial disease that is passed on from parent to child through a mutation in their genes. Early symptoms of HD include uncontrolled movements, clumsiness, and balance problems. Later, HD can take away the ability to walk, talk, and swallow. The Huntington Disease pipeline market research report provides comprehensive information on the therapeutics under development for Huntington Disease (Central Nervous...